MGX
Income statement / Annual
Last year (2023), Metagenomi, Inc. Common Stock's total revenue was $44.76 M,
an increase of 160.21% from the previous year.
In 2023, Metagenomi, Inc. Common Stock's net income was -$68.26 M.
See Metagenomi, Inc. Common Stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$44.76 M
|
$17.20 M
|
$243,000.00
|
| Cost of Revenue |
$94.40 M |
$1.73 M |
$387,000.00 |
| Gross Profit |
-$49.65 M |
$15.47 M |
-$144,000.00 |
| Gross Profit Ratio |
-1.11 |
0.9 |
-0.59 |
| Research and Development
Expenses |
$94.40 M
|
$43.14 M
|
$14.48 M
|
| General & Administrative
Expenses |
$28.85 M
|
$18.70 M
|
$9.71 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$28.85 M
|
$18.70 M
|
$9.71 M
|
| Other Expenses |
$0.00 |
$201,000.00 |
$4,000.00 |
| Operating Expenses |
$28.85 M |
$61.84 M |
$24.19 M |
| Cost And Expenses |
$123.25 M |
$61.84 M |
$24.19 M |
| Interest Income |
$15.47 M |
$3.42 M |
$43,000.00 |
| Interest Expense |
$0.00 |
$98,000.00 |
$302,000.00 |
| Depreciation &
Amortization |
$4.21 M
|
$1.73 M
|
$387,000.00
|
| EBITDA |
-$56.02 M
|
-$39.19 M
|
-$20.75 M
|
| EBITDA Ratio |
-1.25 |
-2.28 |
-96.76 |
| Operating Income Ratio
|
-1.75
|
-2.6
|
-98.55
|
| Total Other
Income/Expenses Net |
$18.26 M
|
$3.62 M
|
$2.51 M
|
| Income Before Tax |
-$60.23 M |
-$41.02 M |
-$21.44 M |
| Income Before Tax Ratio
|
-1.35
|
-2.39
|
-88.24
|
| Income Tax Expense |
$8.03 M |
$2.57 M |
$306,000.00 |
| Net Income |
-$68.26 M |
-$43.59 M |
-$21.44 M |
| Net Income Ratio |
-1.53 |
-2.53 |
-88.24 |
| EPS |
-1.82 |
-1.45 |
-0.72 |
| EPS Diluted |
-1.82 |
-1.45 |
-0.72 |
| Weighted Average Shares
Out |
$37.53 M
|
$29.96 M
|
$29.96 M
|
| Weighted Average Shares
Out Diluted |
$37.53 M
|
$29.96 M
|
$29.96 M
|
| Link |
|
|
|
